# LLM call: summary

- Turn: 13
- Sequence: 7
- Model: meta/muse-spark-1.3-contributor
- Prompt tokens: 814
- Completion tokens: 339
- Total tokens: 1153
- Cost (USD): 0.000149

## System prompt


```
# System Prompt: Summarizer

This is part of an AI-driven scenario simulation. You are the Archivist for a scenario simulation. Your task is to maintain a concise historical record of important events and decisions.

You will receive:

1. The current `historical_summary` (summary of all previous turns)
2. The `narrative` from the latest turn

Your goal is to create a new historical summary, incorporating the narrative from the latest turn.

**Guidelines:**

* **Be Concise:** Condense the new information significantly. Focus on major events and decisions.
* **Maintain Continuity:** Ensure the summary reads as a coherent history of the world.
* **Filter Noise:** Remove minor details or color text that doesn't impact the long-term state.
* **Language:** Write in the same language as the input text.

Respond ONLY with the updated historical summary. Do not add headers or meta-commentary.

```

## User prompt

Template: templates/user-prompts/summarize.md (shared default)

Interpolated into it, in order of appearance:

- characters 20-1226: `{{historical_summary}}` from the run's rolling summary, written by the Game Master

Everything outside those spans is the template's own text.

```
HISTORICAL SUMMARY:
Grid audits to sovereignty package met by cutoff/ransomware, blockades and side deals; bio-continuity shield launched with audited hubs and frozen queue.

Autumn designed-assistance pathogen outbreak from port hospital spread to two regions, contained in seven weeks with military mortuary support by December. Shield ran as incident command — surged sequencing, mandatory genome-model reporting, therapies only via EU-hosted hubs; side-deal capitals stayed frozen, ran parallel supplies without suing. Union credited but resented.

Jan-June recovery: common queue held, Commission offered re-entry only on common terms and tied mayoral payouts to staying inside; most mayors stayed for mortuary/sampling support. Emergency waivers/stipends/rehires for sequencing and wastewater teams slowly restaffed some hubs by spring, oversight still thin, trainee uptake stalled. Japan-Korea-middle-power coordination initialled in November advanced only procedurally — licence alignment, joint compute bargaining, eval pool as joint asset — partners demanded guaranteed inputs/slots, approvals slipped to next semester. Delivery beginning, not delivered; resentment over frozen queues and publication rules festered.

CURRENT NARRATIVE:
### Outside the room where it happened
Washington and Beijing announced a limited pact on weights security, escalation safeguards and controls on biological design tools. Verification was thin but real — inspections, incident channels, a follow-on group to write the details. Brussels learned the outlines hours before the cameras, not months before in a drafting room.

The Commission scrambled to turn exclusion into an entry ticket. Envoys offered Europe's licence-alignment work with Japan and Korea and its small evaluation pool as a verification contribution, and promised to transpose the new controls through existing AI and dual-use law. HERA moved to require clearance for genome-model work through audited hubs before funding or publication sign-off, aligning with a WHO-led inquiry that blamed published methods for enabling last autumn's designed-pathogen outbreak.

### A compact delivered, a queue still resented
The middle-power containment compact concluded its initial phase: shared lists, joint bargaining language, and a first tranche of therapy inputs routed through the common queue. Partners still withheld final approvals, demanding guaranteed slots before committing further.

At home, the staffing surge kept clinics and sampling routes running. Night shifts were covered again in several hub cities, wastewater teams rehired, mayoral payouts still tied to staying inside the common queue. The two capitals running parallel supplies stayed outside, now told that audit compliance was also the ticket to any shared verification slots. They did not sue, and they did not return.

Journals and funders split bitterly over binding pre-publication review. Researchers warned of censorship; health officials warned of repetition. Oversight remained thin, trainees scarce, and resentment over frozen queues deepened even as wards stayed empty.

Brussels ended the year with a plausible bid for relevance — a verifier that could show it verified what it signed — but still waiting outside the room, asking to be let in before procedures hardened without it.
```

## Raw response

```
Grid audits to sovereignty package met by cutoff/ransomware, blockades and side deals; bio-continuity shield launched with audited hubs and frozen queue.

Autumn designed-assistance pathogen outbreak from port hospital spread to two regions, contained in seven weeks with military mortuary support by December. Shield ran as incident command — surged sequencing, mandatory genome-model reporting, therapies only via EU-hosted hubs; side-deal capitals stayed frozen, ran parallel supplies without suing. Union credited but resented.

Jan-June recovery: common queue held, Commission tied mayoral payouts to staying inside; waivers/stipends/rehires restaffed some hubs by spring, oversight thin, trainee uptake stalled. Japan-Korea-middle-power coordination advanced only procedurally — licence alignment, joint compute bargaining, eval pool as joint asset — partners demanded guaranteed inputs/slots, approvals slipped.

Year-end: US-China limited pact on weights security, escalation safeguards, biological design-tool controls with thin verification; Brussels learned late, offered licence work and eval pool as verification contribution, promised transposition via AI/dual-use law, HERA required hub clearance before funding/publication. Middle-power compact delivered first tranche via common queue but withheld final approvals pending guaranteed slots. Staffing surge covered clinics/sampling, parallel-supply capitals still outside and now told audit compliance required for verification slots — did not sue or return. Pre-publication review split journals/funders, oversight thin, frozen-queue resentment deepened. Brussels bid as verifier, still outside room.
```
